title: Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma.
abstract: BACKGROUND
  Numerous treatments are available for cutaneous T-cell lymphoma (CTCL), including systemic retinoids. Very few data are available on topical retinoids.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the safety and efficiency of tazarotene as monotherapy for early-stage CTCL.
  
  
  METHODS
  An open-label, prospective study of tazarotene as monotherapy for stages IA to IIA CTCL was conducted. Index lesions on 10 patients were followed for 6 months on treatment, plus at least 6 months off treatment.
  
  
  RESULTS
  Six patients (60%) showed complete response (CR). Erythema, scaling, thickness, and lesion area decreased progressively throughout treatment. The mean time to CR was 3.8 months; CR was durable for at least 6 months in 83%. Of the 4 patients (40%) without CR, 2 (20%) had stable disease and 2 (20%) stopped the medication because of local side effects; none showed progression.
  
  
  CONCLUSIONS
  This is the first Canadian trial providing evidence that topical tazarotene has excellent potential as a monotherapy agent for stages I to IIA CTCL.
authors.affiliation: McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada Université de Montréal, Montreal, QC, Canada.
authors.forename: Catherine
authors.initials: C
authors.lastname: Besner Morin
authors.affiliation: McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada Université de Montréal, Montreal, QC, Canada McGill University, Montreal, QC, Canada.
authors.forename: David
authors.initials: D
authors.lastname: Roberge
authors.affiliation: Fredericton, NB, Canada.
authors.forename: Irina
authors.initials: I
authors.lastname: Turchin
authors.affiliation: McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada McGill University, Montreal, QC, Canada.
authors.forename: Tina
authors.initials: T
authors.lastname: Petrogiannis-Haliotis
authors.affiliation: McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada McGill University, Montreal, QC, Canada.
authors.forename: Gizelle
authors.initials: G
authors.lastname: Popradi
authors.affiliation: McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada McGill University, Montreal, QC, Canada pehrkevin@sympatico.ca.
authors.forename: Kevin
authors.initials: K
authors.lastname: Pehr
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D055815:Young Adult; D012176:Retinoids
chemical_list: D000970:Antineoplastic Agents; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids
keywords: CTCL; cutaneous lymphoma; dermatology; retinoids; tazarotene